EXPERIENCE IN TREATMENT OF PATIENTS WITH H. PYLORI-ASSOCIATED DISEASES

Abstract

Efforts are under way to find optimal therapy for Helicobacter pylori (H. Pylori)-associated gastrointestinal diseases. Among such diseases are gastric and duodenal ulcers, gastritis (atrophic gastritis), functional dyspepsia, gastropathies induced by non-steroidal antiulcer drugs (NSAIDs). Various regimens for eradication of Helicobacter pylori infection are typically chosen on the basis of administration of proton pump inhibitors (PPI), antibiotics, metronidazole in different doses and combinations, as well as bismuth salts products, mainly bismuth tripotassium dicitrate (BTD). The article explores the possibility for participation in the eradication therapy regimens with a domestic BTD-based drug – Novobismol®. The studies showed that Novobismol® was successfully used in anti-Helicobacter therapy in patients with peptic ulcer, chronic gastritis, and in patients with functional dyspepsia. It can be concluded that the BTD-based drug Novobismol® is effective and safe, and its use extends the possibilities of treating H. Pylori-associated diseases.

Keywords

• bismuth products
• novobismol®
• hp-associated diseases
• treatment